Diabetes and hypertension: A position statement by the American diabetes association

Diabetes Care

Volumn 40, Issue 9, 2017, Pages 1273-1284

  De Boer, Ian H ^a   Bangalore, Sripal ^b   Benetos, Athanase ^c   Davis, Andrew M ^d   Michos, Erin D ^e   Muntner, Paul ^f   Rossing, Peter ^g   Zoungas, Sophia ^h   Bakris, George ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85028072849     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci17-0026     Document Type: Article

References (137)

1. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement fromthe American Heart Association and American Diabetes Association. Circulation 2014;130:1110-1130
2. Fox CS, Golden SH, Anderson C, et al.; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015;38:1777-1803
3. Arauz-Pacheco C, Parrott MA, Raskin P; American DiabetesAssociation. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26(Suppl. 1):S80-S82
4. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 2015;313:603-615
5. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet 2016;387:957-967
6. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016;352:i717
7. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetesmellitus/impaired fasting glucose: observations from traditional and Bayesian randomeffects meta-analyses of randomized trials. Circulation 2011;123:2799-2810
8. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overviewandmeta-analyses of randomized trials. J Hypertens 2017;35:922-944
9. Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298-2307
10. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-1523
11. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017;376:1407-1418
12. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl JMed 2013; 368:1613-1624
13. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 2016;316:602-610
14. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-2398
15. Pickering TG, Hall JE, Appel LJ, et al.; Subcommittee of Professional and Public Education of the AmericanHeart Association Council onHigh Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45: 142-161
16. Powers BJ, OlsenMK, Smith VA,Woolson RF, Bosworth HB, Oddone EZ. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med 2011;154:781-788
17. Bakris GL. The implications of blood pressure measurement methods on treatment targets for blood pressure. Circulation 2016;134:904-905
18. CushmanWC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
19. Wright JT Jr, Williamson JD, Whelton PK, et al.; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116
20. MyersMG, ValdiviesoM, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens 2009; 27:280-286
21. MyersMG, GodwinM, DawesM, Kiss A, Tobe SW, Kaczorowski J. The conventional versus automated measurement of blood pressure in the office (CAMBO) trial: masked hypertension substudy. J Hypertens 2012;30:1937-1941
22. Agarwal R. Implications of blood pressure measurement technique for implementation of Systolic Blood Pressure Intervention Trial (SPRINT). J Am Heart Assoc 2017;6:e004536
23. Myers MG, Campbell NRC. Unfounded concerns about the use of automated office blood pressure measurement in SPRINT. J Am Soc Hypertens 2016;10:903-905
24. Tuttle KR, Bakris GL, BilousRW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014;37:2864-2883
25. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment ofHigh Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572
26. Adamsson Eryd S, Gudbjörnsdottir S, Manhem K, et al. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ 2016;354:i4070
27. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 2017;317:165-182
28. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
29. Heart OutcomesPrevention Evaluation Study Investigators. Effects of ramipril on cardiovascular andmicrovascular outcomes in people with diabetesmellitus: results of the HOPE study andMICROHOPE substudy. Lancet 2000;355:253-259
30. Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. Hypertens Res 2007;30: 479-488
31. Kikuya M, Hansen TW, Thijs L, et al.; IDACO investigators.Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Blood Press Monit 2007;12:393-395
32. Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. Hypertension 2013; 62:982-987
33. Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension 2014;63:675-682
34. Yano Y, Bakris GL. Recognition and management of masked hypertension: a reviewand novel approach. J Am Soc Hypertens 2013;7:244-252
35. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40:136-154
36. Freeman R,WielingW, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011;161:46-48
37. Fleg JL, Evans GW, Margolis KL, et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial: prevalence, incidence, and prognostic significance. Hypertension 2016;68:888-895
38. Briasoulis A, Silver A, Yano Y, Bakris GL. Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. J Clin Hypertens (Greenwich) 2014;16:141-148
39. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascularmortality: ameta-analysis of individual data for onemillion adults in 61 prospective studies. Lancet 2002;360:1903-1913
40. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-443
41. Zoungas S, de Galan BE, Ninomiya T, et al.; ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009;32:2068-2074
42. Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 2014; 37:1721-1728
43. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular andmicrovascular outcomes in patients with type 2 diabetesmellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840
44. American Diabetes Association. Glycemic targets. Sec.6 In Standards of Medical Care in Diabetesd2017.DiabetesCare 2017;40(Suppl.1): S48-S56
45. Sundström J, Arima H, Woodward M, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384:591-598
46. Franklin SS. Cardiovascular risks related to increased diastolic, systolic and pulse pressure. An epidemiologist's point of view. Pathol Biol (Paris) 1999;47:594-603
47. Franklin SS, Gustin W 4th, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The FraminghamHeart Study. Circulation 1997;96:308-315
48. Whelton PK, Appel L, Charleston RN, et al. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I [published correction appears in JAMA 1992;267:2330]. JAMA 1992;267:1213-1220
49. Appel LJ, Champagne CM, Harsha DW, et al.; Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003;289: 2083-2093
50. Azadbakht L, FardNRP, KarimiM, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care 2011;34:55-57
51. Chen L, Pei J-H, Kuang J, et al. Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism 2015;64:338-347
52. Lin JS, O'Connor EA, Evans CV, Senger CA, Rowland MG, Groom HC. Behavioral Counseling to Promote a Healthy Lifestyle for Cardiovascular Disease Prevention in Persons With Cardiovascular Risk Factors: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet], 2014. Rockville, MD, Agency for Healthcare Research andQuality (US), 2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK241537/. Accessed 11 November 2016
53. Sacks FM, Svetkey LP, Vollmer WM, et al.; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10
54. Young DR, Hivert MF, Alhassan S, et al.; Endorsed by The Obesity Society; Physical Activity Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Stroke Council. Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the American Heart Association. Circulation 2016;134:e262-e279
55. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report fromthe panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520
56. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann InternMed 1994;121: 289-300
57. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002;25:134-147
58. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension 2013;61:1360-1383
59. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care 2016;39:2065-2079
60. Semlitsch T, Jeitler K, Berghold A, et al. Longterm effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2016;Mar 3:CD008274
61. ShawJE, PunjabiNM,NaughtonMT, et al. The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. Am J Respir Crit Care Med 2016;194:486-492
62. Bakris GL, Weir MR; Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patientswith type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003;5:202-209
63. Feldman RD, Zou GY, VandervoortMK, Wong CJ, Nelson SAE, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53:646-653
64. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719
65. Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med 2016;13:e1001971
66. Palmer SC,MavridisD,Navarese E, et al. Comparative efficacy and safety of blood pressurelowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015; 385:2047-2056
67. Barzilay JI, Davis BR, Bettencourt J, et al.; ALLHAT Collaborative Research Group. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich) 2004;6:116-125
68. Weber MA, Bakris GL, Jamerson K, et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010;56: 77-85
69. Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin systemblockers: systematic review and meta-analysis of randomized trials. BMJ 2016;352:i438
70. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-1689
71. Yusuf S, Teo KK, Pogue J, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events.N Engl JMed 2008;358:1547-1559
72. Fried LF, Emanuele N, Zhang JH, et al.; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-1903
73. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013;346:f360
74. Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl JMed 2008;359:2417-2428
75. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: 1456-1462
76. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
77. Lewis EJ, Hunsicker LG, ClarkeWR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
78. Whelton PK, Barzilay J, Cushman WC, et al.; ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-1409
79. Remonti LR, Dias S, Leitão CB, et al. Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetesdnetwork meta-analysis of randomized trials. J Diabetes Complications 2016;30:1192-1200
80. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603
81. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl JMed 1998;338: 645-652
82. Schrier RW, Estacio RO,Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetesmellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007;3:428-438
83. Barnett AH, Bain SC, Bouter P, et al.; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-1961
84. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014;34: 333-339
85. KhoslaN, Kalaitzidis R, BakrisGL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418-424
86. Agarwal R, Sinha AD, PappasMK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol 2014;39:171-182
87. Sica DA. Diuretic use in renal disease. Nat Rev Nephrol 2011;8:100-109
88. Parving H-H, Brenner BM, McMurray JJV, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-2213
89. Zhao P, Xu P, Wan C, Wang Z. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev 2011;Oct 5: CD004184
90. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of time of day of blood pressurelowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011;34:1270-1276
91. Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011;22:2313-2321
92. Ralston JD, Cook AJ, Anderson ML, et al. Home blood pressure monitoring, secure electronic messaging and medication intensification for improving hypertension control: a mediation analysis. Appl Clin Inform 2014;5:232-248
93. Grant S, Greenfield SM,Nouwen A,McManus RJ. Improving management and effectiveness of home blood pressure monitoring: a qualitative UK primary carestudy. Br J Gen Pract 2015;65:e776-e783
94. Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens 2013; 31:455-467; discussion 467-468
95. DeAlleaume L, Parnes B, Zittleman L, et al. Success in the Achieving CARdiovascular Excellence in Colorado (A CARE) home blood pressure monitoring program: a report from the Shared Networks of Colorado Ambulatory Practices and Partners (SNOCAP). J Am Board Fam Med 2015; 28:548-555
96. Juhanoja EP, Niiranen TJ, Johansson JK, Puukka PJ, Jula AM. Agreement between ambulatory, home, and office blood pressure variability. J Hypertens 2016;34:61-67
97. Ntineri A, Stergiou GS, Thijs L, et al. Relationship between office and home blood pressure with increasing age: The International Database of HOme blood pressure in relation to CardiovascularOutcome (IDHOCO). Hypertens Res 2016;39: 612-617
98. Bobrie G, Genès N, Vaur L, et al. Is "isolated home" hypertension as opposed to "isolated office" hypertension a sign of greater cardiovascular risk? Arch Intern Med 2001;161:2205-2211
99. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005;111:1777-1783
100. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012; 380:601-610
101. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
102. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: ameta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:457-466
103. Oliva RV, BakrisGL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014;8:330-339
104. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review andmeta-analyses of randomised controlled trials. BMJ 2012;344:d7771
105. Iliescu R, Lohmeier TE, Tudorancea I, LaffinL, Bakris GL. Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol 2015;309: F583-F594
106. Raheja P, Price A,Wang Z, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 2012;60: 319-325
107. Bakris GL, Agarwal R, Chan JC, et al.; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015;314:884-894
108. Williams B,MacDonald TM,Morant S, et al.; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-2068
109. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetesmellitus and/or chronic kidney disease. Eur Heart J 2016;37:2105-2114
110. Bomback AS, Klemmer PJ.Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012;33:119-124
111. BakrisGL, Pitt B,WeirMR, et al.; AMETHYSTDN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial [published correction appears in JAMA 2015]. JAMA 2015;314:731
112. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-1131
113. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014;Feb 6:CD002252
114. LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:819-826
115. Al-Balas M, Bozzo P, Einarson A. Use of diuretics during pregnancy. Can Fam Physician 2009;55:44-45
116. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003;107:2864-2869
117. Franklin SS, LarsonMG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001;103:1245-1249
118. Salvi P, SafarME, Labat C, Borghi C, Lacolley P, Benetos A; PARTAGE Study Investigators. Heart disease and changes in pulse wave velocity and pulse pressure amplification in the elderly over 80 years: the PARTAGE Study. J Hypertens 2010; 28:2127-2133
119. Rönnback M, Fagerudd J, Forsblom C, Pettersson-Fernholm K, Reunanen A, Groop PH; Finnish Diabetic Nephropathy (FinnDiane) Study Group. Altered age-related blood pressure pattern in type 1 diabetes. Circulation 2004;110: 1076-1082
120. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995;91:1432-1443
121. Schram MT, Kostense PJ, Van Dijk RA, et al. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens 2002;20: 1743-1751
122. Bruce DG, Casey GP, Grange V, et al.; Fremantle Cognition in Diabetes Study. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study. Diabetes Res Clin Pract 2003;61:59-67
123. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 2015;11:718-726
124. Satizabal C, Beiser AS, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 2016;375:93-94
125. Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA 2015; 314:170-180
126. Benetos A, Bulpitt CJ, Petrovic M, et al. An expert opinion from the European Society of Hypertension-European Union GeriatricMedicine Society Working Group on the management of hypertension in very old, frail subjects. Hypertension 2016;67:820-825
127. Yano Y, Rakugi H, Bakris GL, et al. Ontreatment blood pressure and cardiovascular outcomes in older adults with isolated systolic hypertension. Hypertension 2017;69:220-227
128. Vamos EP, Harris M, Millett C, et al. Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ 2012;345:e5567
129. Vidal-Petiot E, Ford I, Greenlaw N, et al.; CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016;388:2142-2152
130. McEvoy JW, Chen Y, Rawlings A, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol 2016; 68:1713-1722
131. Haller H, Ito S, Izzo JL Jr, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-917
132. MauerM, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51
133. Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 2013;62:3224-3231
134. Zoungas S, Chalmers J, Neal B, et al.; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.NEngl JMed 2014;371:1392-1406
135. Hansson L, Zanchetti A, Carruthers SG, et al.; HOT Study Group. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762
136. Calhoun DA, Jones D, Textor S, et al.; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-e526
137. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005;18:1422-1428